-- 据周四提交给澳大利亚证券交易所的文件显示，Orthocell（ASX：OCC）已在加拿大完成其Remplir神经修复装置的首次商业销售，这是其外周神经重建产品全球推广进程中的一个里程碑。 该公司表示，Remplir目前已获准在澳大利亚、新西兰、美国、新加坡、香港和加拿大销售并产生收入，并计划在2026年下半年获得欧盟和英国市场的批准后，进一步拓展市场。 Orthocell补充道，截至3月31日，公司持有超过4800万澳元的现金，且无任何债务。
Related Articles
International
Saudi Arabia's Quarterly GDP Down 1.5% in Q1, Flash Data Shows
Saudi Arabia's seasonally adjusted real gross domestic product decreased 1.5% on a quarterly basis in the first quarter, compared with a 1.4% rise in the prior three-month period, flash data from the General Authority for Statistics showed Thursday.Annually, the Saudi Arabian economy grew 2.8% during the three-month period, after a 5% increase in the previous quarter.
$^TASI
Asia
Diagens Biotechnology's 2025 Loss Widens
Hangzhou Diagens Biotechnology (HKG:2526) booked 67.1 million yuan in attributable loss for 2025, widening from a loss of 43.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.The medical imaging products maker's shares gained nearly 3% in afternoon trade Thursday.Loss per share was 0.84 yuan, compared with 0.55 yuan in 2024.Revenue more than doubled year on year to 164.4 million yuan from 70.4 million yuan.
$HKG:2526
Asia
Daqin Railway Q1 Profit Down 7%; Shares Slip 3%
Daqin Railway Co (SHA:601006) posted first-quarter attributable net profit of 2.38 billion yuan, down 6.9% from 2.56 billion yuan the previous year.Earnings per share slid to 0.12 yuan from 0.13 yuan, according to a Thursday filing with the Shanghai bourse.Operating revenue climbed 4.3% year over year to 18.6 billion yuan from 17.8 billion yuan.Shares of the railway operator declined 3% in recent trade.
$SHA:601006